Preprint
Case Report

Deteriorating Atrioventricular Block in COVID-19 Suspected Patient after Receiving Initial Dose of Azythromycin and Hydroxychloroquine

Submitted:

09 May 2020

Posted:

11 May 2020

You are already at the latest version

Abstract
Coronavirus 2019 (COVID-19) is an infectious disease that is becoming a pandemic. Hydroxychloroquine in combination with azythromycin are among drugs currently in use to eradicate COVID-19. Despite concerns due to its potential cardiac toxicity, hydroxychloroquine is widely accepted in mild and moderate COVID-19 pneumonia. In this case report, we report a case of a young Indonesian adult male with suspected COVID-19 pneumonia who received hydroxychloroquine and azythromycin therapies and during 24 hour experienced deterioration of atrioventricular block.
Keywords: 
COVID-19; azythromycin; hydroxychloroquine; atrioventricular block
Subject: 
Medicine and Pharmacology  -   Cardiac and Cardiovascular Systems
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Altmetrics

Downloads

531

Views

672

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2025 MDPI (Basel, Switzerland) unless otherwise stated